Karim Fizazi, MD, PhD, Institute Gustave Roussy, and Christopher Wallis, MD, PhD, University of Toronto, detail the latest updates regarding the phase 3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line treatment for patients with mCRPC harboring homologous recombination repair gene alterations. View more ASCO 2023 videos. ...
Advertisement
Advertisement
Latest News
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
dd-MVAC provides a better OS at 5 years compared with GC in the perioperative setting for patients with MIBC.
Updated PFS data was presented for the first phase 3, randomized trial to test the benefit of ICI rechallenge in mRCC.
Dr. Deek highlights his analysis of NRG RTOG 0524 and 0712 for prognostic significance of immune cell infiltration in MIBC.
Dr. Garje provides survival outcomes of sarcomatoid UC in patients with T2-T4, N0-N1 bladder cancer after definitive therapy.
Drs. Calais, Wallis discuss a post-hoc that showed PSMA PET as effective for treating pelvic, extrapelvic recurrent PC.
Dr. Voss highlights the research concerning IO-TKI combination, triplets, and other treatment approaches for RCC.
Drs. Armstrong and Wallis discuss the design of an AI-derived pathology-based biomarker for localized high-risk prostate.
CBM588 may improve clinical outcomes for patients with mRCC when combined with the cabozantinib plus nivolumab.
The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress.
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
Expert Interviews
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer.
Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
Dr. A. Ari Hakimi discusses how cytoreductive nephrectomy has evolved and is being used in today’s mRCC treatment paradigm.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
dd-MVAC provides a better OS at 5 years compared with GC in the perioperative setting for patients with MIBC.
Updated PFS data was presented for the first phase 3, randomized trial to test the benefit of ICI rechallenge in mRCC.
Video Insights
Clinical discussions with experts in the field
